sox040713 Saturday, 05/12/18 02:21:46 AM Re: frro

sox040713 Saturday, 05/12/18 02:21:46 AM
Re: frrol post# 227770
Post # 227953 of 228019

I agree with your take in the 10-Q. Now let’s focus on the PR. In the second bullet point,

Quote:

---

A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;

---

That was the language Leo used when looking to hire a contractor. Now we know the name is Evonik. The second paragraph under “Brilacidin-Dermatology Formulation Development” was the one I quoted.

Quote:

---

To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.

---

If Leo was looking to simply hire a formulator, he would’ve used lanaguage similar to the first quote. Instead he used words such as negotiations, terms and strategic partnership. That tells me B-Dermatitis is the second indication currently under negotiations for a deal.

http://www.ipharminc.com/press-release/2018/1...-diseasesd